Molecular and Applied Aspects of Oxidative Drug Metabolizing Enzymes

[1]  A. Garrod.  The Incidence of Alkaptonuria: A study in Chemical Individuality , 1996, Nutrition reviews.

[2]  L. Bertilsson,et al.  Polymorphic Drug Oxidation , 1996 .

[3]  J. Benítez,et al.  Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population , 1995, Clinical pharmacology and therapeutics.

[4]  M. Eichelbaum,et al.  Unpredictability of Flecainide Plasma Concentrations in Patients with Renal Failure: Relationship to Side Effects and Sudden Death? , 1994, Therapeutic drug monitoring.

[5]  U. Meyer,et al.  Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. , 1992, Genomics.

[6]  M. Hoseyni.  Risk assessment for aflatoxin: III. Modeling the relative risk of hepatocellular carcinoma. , 1992, Risk analysis : an official publication of the Society for Risk Analysis.

[7]  E. Buchert,et al.  Clinical implications of variable antiarrhythmic drug metabolism. , 1992, Pharmacogenetics.

[8]  N. Gorelick.  Risk assessment for aflatoxin: I. Metabolism of aflatoxin B1 by different species. , 1990, Risk analysis : an official publication of the Society for Risk Analysis.

[9]  T. Kuiper-Goodman.  Uncertainties in the risk assessment of three mycotoxins: aflatoxin, ochratoxin, and zearalenone. , 1990, Canadian journal of physiology and pharmacology.

[10]  K. Brøsen,et al.  First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype , 1988, Clinical pharmacology and therapeutics.

[11]  C R Dichter,et al.  Risk estimates of liver cancer due to aflatoxin exposure from peanuts and peanut products. , 1984, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[12]  A. S. Gross,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.

[13]  R. Skoda,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. , 1990, Pharmacology & therapeutics.

[14]  H. Neumann,et al.  Differences in aflatoxin B1-susceptibility of rat and mouse are correlated with the capability in vitro to inactivate aflatoxin B1-epoxide. , 1981, Carcinogenesis.

[15]  H GRUNEBERG,et al.  Human genetics. , 1947, The Eugenics review.

[16]  Seung Choi,et al.  ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? J ? ? J ? ? ? ? ? ? ? ? ? ? ? ? ? ? , 2022 .